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Introduction: Mucinous cystic neoplasm (MCN) and solid pseudopapillary neoplasm (SPN) of the
pancreas are uncommon hormone-related pancreatic tumors (HRPTs) with a clear predominance in
young women. This trial aims to investigate the possible association between HRPTs development in
males and phenotypic and sex hormone alterations.
Methods: We performed a retrospective analysis of our database between February 1990 and February
2012. Risk factors for sexual dysfunction were considered exclusion criteria. We investigated secondary
sexual characteristics development, sex hormone level and overall sexual dysfunction degree according
with the International Index of Erectile Function Questionnaire (IIEF).
Results: We initially identiﬁed 25 patients [(MCN: n¼ 16 (64%); SPN: n¼ 9 (36%)]. At follow-up, 5 patients
were lost, 8 resulted dead and 3 were excluded according to exclusion criteria. We ﬁnally enrolled 9
patients (MCN: n¼ 5; SPN: n¼ 4). Puberty occurredwithin physiological age for 7 patients, whereas it was
delayed in 2 cases. Three patients revealed mild to moderate sexual dysfunction, along with low testos-
terone level in two cases. One patient presented hormonal alteration with a normal IIEF score.
Discussion: In this study, the ﬁrst in literature with similar aim, hormonal and/or sexual dysfunction was
present in 4 out of 9 patients affected by HRPT. The rarity of these lesions makes further trials to be
needed for reliable conclusions.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Mucinous cystic neoplasm (MCN) and solid pseudopapillary
neoplasm (SPN) of the pancreas are uncommon hormone-related
pancreatic tumors (HRPT) with a clear predominance in young
women. According to WHO1 and AFIP2 classiﬁcation, the presence
of ovarian like stroma and the lack of communication between the
tumor and the pancreatic duct are mandatory for MCN diagnosis.
Nevertheless, SPNs are considered rare low-grade malignancies
showing amale/female ratio equal to 1/9 and a good prognosis after
radical surgery.3,4
Both entities are characterizedbyawell-documented expression of
sex female hormone receptors that has led many authors to partially
explain their female prevalence, but the histological origin and clinical
implications related are still unclear. This study, theﬁrst in literaturewith
similaraim,focusedonthepossibleassociationbetweenphenotypicand/or
sex hormone level alterations and HRPT development inmale patients.iazzale LA Scuro, 10, 37134
124622.
ciates Ltd. Published by Elsevier Lt2. Methods
This study was approved by the institutional review board and all patients
enrolled gave a speciﬁc informed consent. We performed a retrospective analysis of
our database between February 1990 to February 2012 searching for male patients
who underwent surgical treatment of the primary and with a histologically
conﬁrmed diagnosis of one of the following: mucinous cystadenoma (CAD),
borderline cystadenoma (BLCAD), cystadenocarcinoma (CAK) or solid pseudopa-
pillary neoplasm (SPN) of the pancreas.
We excluded those patients who presented one or more risk factors for sexual
dysfunction such as age greater than 65 years at time of diagnosis, history of severe
diabetes, alcohol excess (more than 50 g per day), drug consumption, arterial
hypertension requiring b-blockers therapy, dyslipidemia. For each patient we
investigated the development of secondary sexual characteristics and analyzed the
dosage of sex hormones. Puberty was considered physiological if occurred between
the age 11 and 14. The International Index of Erectile Function Questionnaire (IIEF)
was used to assess the overall sexual dysfunction degree before the diagnosis.3. Statistics
Descriptive statistical analyses were performed using SPSS
package software 17.0 (SPSS, Chicago, IL). Normally distributed
continuous variables were reported as percentage, mean and
standard deviation. Median and ranges were used to described. All rights reserved.
Table 1
Demographics and clinical features of HRPTs (N ¼ 246).
Male patients
(N ¼ 25) (%)
Female
patients
(N ¼ 221) (%)
P value OR (CI: 95%)
Age (SD) 52 (16) 43 (15) 0.004 e
Abdominal
pain
9 (36) 114 (51.6) 0.205 1.894 (0.803e4.468)
Jaundice 4 (16) 4 (1.8) 0.004 0.097 (0.023e0.415)
Anorexia 6 (24) 24 (10.9) 0.097 0.386 (0.140e1.060)
Weight loss 7 (28) 49 (22.2) 0.684 0.733 (0.289e1.855)
Histology
MCNs 16 (64) 172 (77.8) 0.195 0.506 (0.211e1.216)
SPNs 9 (36) 49 (22.2)
Tumour site
Uncinate
process/head
11 (44) 31 (14) 0.001 0.208 (0.086e0.499)
Body/tail 14 (56) 190 (86)
Palliative
surgery
7 (28) 24 (10.9) 0.024 3.192 (1.210e8.424)
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ORIGINAL RESEARCHnon-parametric variables. At univariate analysis, categorical values
were compared using the c2 test or the Fischer exact test when
expected cell count was less than 5. A P value  0.05 was
considered signiﬁcant.
4. Results
In the study period we initially identiﬁed 246 patients, of which
25 (10.2%) were male and 221 (89.8%) female (M/F ratio: 1/9).
Patients affected by MCN were 188 (76.4%) and 58 (23.6%) were
those with SPN. Within mucinous neoplasms, mucinous cys-
tadenomas, borderline tumors andmucinous cystadenocarcinomas
were 37.2% (n¼ 70), 33% (n¼ 62) and 29.8% (n¼ 56), respectively. In
MCNs group the male/female ratio was 1/11 (n ¼ 16/172), while it
was 1/5 (n ¼ 9/49) for SPNs (P ¼ 0.195; OR ¼ 0.5; CI 95%: 0.211e
1.216). Demographics and clinicopathologic features of the study
cohort are illustrated in Table 1. Within themale group (n¼ 25), the
mean age of those with mucinous neoplasms (n ¼ 16) and solid
pseudopapillary neoplasms (n ¼ 9) was 60.1 (SD: 11.5) and 38.8
years (SD: 15), respectively, and the difference is statistically
signiﬁcant (P: 0.01; CI 95%: 10.2e32.4). The same data shows
a statistically signiﬁcant differencewhen compared to themean age
of females within the group of MCNs (46.7 years; P < 0.0001; CI
95%: 6.182e20.470) and SPNs (29.4 years; P¼ 0.038; CI 95%: 0.536e
18.366). Among the 25 male patients of our series, seven (28%; all
with CAK) underwent surgical bypass, while the remaining 18
patients (CAK: n ¼ 1; CAD: n ¼ 6; BLCAD: n ¼ 2; SPN: n ¼ 9), were
treated with either traditional surgical resection (pylorus
preserving pancreaticoduodenectomy: n ¼ 4; distal pancreatec-
tomy: n ¼ 10) or parenchyma sparing resections (enucleation:
n ¼ 1; middle resection: n ¼ 3).Table 2
Clinical history and IIEF score of our series at time of diagnosis.
Case Histotype Age at
diagnosis
Age of
puberty
Erectile
dysfunction
Orgasm
dysfunc
1 CAD 60 16 Mild Mild
2 CAD 43 14 No No
3 BLCAD 49 13 No No
4 SPN 35 13 No No
5 SPN 41 14 No No
6 CAD 36 11 No No
7 SPN 48 14 No No
8 BLCAD 65 15 No No
9 SPN 38 14 No No
CAD: mucinous cystadenoma; BLCAD: borderline mucinous cystadenoma; SPN: solid psSeven (28%) patients, all with CAK, were excluded from the study
because they died of their disease with a median survival of 4 months.
Another patient, who underwent a pancreaticoduodenectomy for
a cystadenocarcinoma, died for causes non-related to surgery 36
months after the operation. None of the cohort’s male patients expe-
rienced perioperative mortality. Of the remaining 17 patients, 5 were
lost at follow-up and 3 were not included according with exclusion
criteria. Hence, the patients we ﬁnally considered in the current study
were 9 (CAD: n ¼ 3; BLCAD: n ¼ 2; SPN: n ¼ 4).
Demographics and IIEF score of our series are described in
Table 2. Median age of the cohort at time of diagnosis was 43 years,
ranging from 35 to 65. Mean interval time between diagnosis and
IIEF assessment was 6.5 years (SD: 4). Puberty occurred within
physiological age for seven patients (Mean: 13.3 years; SD: 1)
while it was mildly delayed in two cases (Cases 1 and 8: 16 and 15
years, respectively). None of the patients showed signs of
gynecomastia from adolescence until surgery. Six patients re-
ported a normal IIEF score at time of diagnosis and three patients
(Cases 1, 2 and 7) revealed mild to moderate sexual dysfunction.
Distal pancreatectomy was the most frequently performed surgical
procedure (n ¼ 6), followed by pylorus preserving pan-
creaticoduodenectomy (n ¼ 1), pancreatic enucleation (n ¼ 1) and
middle pancreatic resection (n ¼ 1).
Table 3 shows the sex hormone level of our series. Five patients
did not present any hormonal alteration. One patient (Case 1)
showed low level of follicle-stimulating hormone (FSH), luteinizing
hormone (LH) and testosterone along with mild sexual dysfunction
at IIEF score. Another patient (Case 6)with low testosterone level and
normal FSH and LH level, reported a secondary azoospermia. Case 7
presented low testosterone level associated to a mild dysfunction
at IIEF score, while case 8 showed high FSH and LH level only, with
no IIEF score or testosterone/progesterone level alteration.5. Discussion
Mucinous cystic neoplasm and solid pseudopapillary neoplasm
are two uncommon pathologic entities within exocrine pancreatic
lesions. Since the WHO1 and AFIP2 deﬁned the lack of communi-
cation with pancreatic duct and the presence of the ovarian like
stroma asmandatory criteria to diagnoseMCN,many authors found
that MCNs were potentially malignant lesions almost exclusively
affecting middle-aged women.5e7 SPN is a low-grade malignancy
with good long-term prognosis after surgical resection, accounting
for around 3% of all pancreatic exocrine neoplasms.4 Similarly to
MCN, SPN shows a clear predominance in young women, being
present in male patients only in 13% of cases.3 Despite this shared
high female prevalence can be partially explained by the expression
of female sex hormone receptor for both mucinous neoplasms8e10
and solid pseudopapillary neoplasms,11 the histological origin still
remains debated.ic
tion
Sexual desire
alteration
Intercourse satisfaction
alteration
Overall satisfaction
alteration
Moderate Moderate Mild
Mild No No
No No No
No No No
No No No
No No No
No Mild Mild
No No No
No No No
eudopapillary neoplasm.
Table 3
Sex hormone level of our series at time of assessment.
Case FSH
(Nr: 1.5e12.4 U/L)
LH
(Nr: 1.7e8.6 U/L)
Testosterone
(Nr: 7.6e31.4 nmol/L)
Progesterone
(Nr: 0.7e4.3 nmol/L)
17-b-Estradiol
(Nr: 28e156 pmol/L)
Prolactin
(Nr: 4.6e21 ng/mL)
1 0.9 0.4 3.3 0.7 29.2 9.9
2 6.6 2.8 9.4 1.1 44.2 9.8
3 4.3 6.7 15.1 1.8 48.4 7.7
4 4.7 3.5 10.8 2.3 61 8.2
5 5.8 6.2 12.4 2.1 85 6.4
6 4.7 4.2 5.4 1.6 104.4 7.8
7 4.7 6.3 6.3 0.9 94 5.1
8 19 31 11.1 <0.1 76.8 7.4
9 1.9 2.1 14.5 1.4 53.2 6.1
Nr: normal range.
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ORIGINAL RESEARCHZamboni et al. hypothesized that MCNmay arise as either (i) the
consequence of the endodermal immature stroma exposure to
female sex hormones (which might lead an original solid lesion to
cystic evolution) or (ii) the presence of ectopic primary yolk cells, as
the pancreatic and the ovarian ridges are strictly adjacent over early
embryogenesis.7 Similar theories have been proposed by several
authors to explain the origin of SPN, supported by the evidence of
progesterone receptor in more than 80% of cases.11e14
Indeed, according with other series, we found that HRPT
location showed a signiﬁcant difference (P ¼ 0.001) when strati-
ﬁed for gender, being almost exclusively located in the pancreatic
body and tail for female patients (86%), and almost equally
distributed between the region of uncinate process/head (44%)
and body/tail (56%) in males. This ﬁnding certainly makes the
discussion about the etiopathogenesis of HRPTs to remain still
controversial.3,5,15 Wouters et al.16 reasonably argued that excess
alcohol consumption may represent a risk factor for MCN devel-
opment in males by increasing the peripheral fat production of
estrogen. However, all the patients included in our series reported
a daily alcohol intake of less than 50 g and showed normal
estrogen and progesterone level. Moreover, in the series of study
of 19 patients having solid pseudopapillary neoplasm by Tien
et al.,17 the authors found no difference in the immunohistologic
staining patterns and presence of sex hormone receptors when
stratiﬁed for gender (M: n ¼ 4; F: n ¼ 15).
Of note, we found a curious difference in clinical presentation
within male patients with MCN or SPN, as they underwent pallia-
tive surgery in a signiﬁcantly higher proportion compared to their
female counterpart (28% vs 10.9%; P ¼ 0.024). This consideration
might lead someone to consider a possible role of routine gyne-
cological investigations in the achievement of an earlier diagnosis
for females. Indeed, in our series incidental diagnosis did not
signiﬁcantly correlate with gender, being reported in 52% and 41.2%
of male and female patients, respectively (P¼ 0.410), and the role of
a possible more aggressive biological behavior of HRPT affecting
males, appears to be uncertain.
Moreover, the role of sex hormones in male patients with HRPT
is still unknown. In our report, clinically signiﬁcant hormonal and/
or sexual dysfunction was present in 4 out of 9 patients affected by
HRPT. However, the small sample size does not allow to clarify
whether these ﬁndings can be considered clinical manifestations
preluding the tumor development or, more simply, secondary
alterations to other common primary sexual dysfunctions (i.e.,
primary hypogonadism or sexual impotence). Nonetheless, two
further points of this study appear to be noteworthy: (1) all male
patients showed normal levels of both progesterone and estrogen;
(2) in line with other main series, they were also signiﬁcantly older
than their female counterparts.3,5,15 This evidence seems to support
the feeling that late occurrence of HRPT in males might originate asthe result of a long-term exposure of the ectopic ovarian like stroma
to normal level of female sex hormones.
In summary, our report documented that preoperative assess-
ment of any possible hormonal or phenotypic alterations in male
patients thought to have HRPT, may be considered worthwhile in
supporting, but not elucidating, the diagnostic suspicion raised at
time of presentation. Unfortunately, the rarity of these lesions and
the retrospective study limitations make the achievement of a large
sample to be particularly difﬁcult. Therefore, further trials based on
homogenous series are needed in future for clinical conclusions.6. Conﬂict of interest statement
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